Oya, M., Armstrong, A. J., Thiery-Vuillemin, A., Shore, N., Procopio, G., Arslan, Ç., … Saad, F. (2022). 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 33, pp. S1495–S1495). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.10.194

Oya, M., A. J. Armstrong, A. Thiery-Vuillemin, N. Shore, G. Procopio, Ç. Arslan, N. Mehra, et al. “157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1495–S1495. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.10.194.

Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan Ç, et al. 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2022. p. S1495–S1495.

Oya, M., et al. “157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1495–S1495. Crossref, doi:10.1016/j.annonc.2022.10.194.

Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan Ç, Mehra N, Parnis F, Brown E, Constans Schlurmann F, Joung JY, Sugimoto M, Sartor O, Liu Y-Z, Poehlein CH, Desai C, Del Rosario PMD, Clarke N, Saad F. 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2022. p. S1495–S1495.